Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFD Technologies Regulatory News (FDP)

  • This share is currently suspended. It was suspended at a price of 2,450.00
  • There is currently no data for FDP

Director/PDMR Shareholding

23 Jan 2009 15:45

RNS Number : 1832M
First Derivatives PLC
23 January 2009
 

23 January 2009

First Derivatives plc

("First Derivatives" or the "Company")

(AIM:FDP.L, IEX:GYQ.I)

Director / PDMR Shareholding Notification

The Board of First Derivatives advises that Mr. Brian Conlon, Chief Executive Officer and founder shareholder, has notified it that in March 2002, prior to the Company's admission to AIM or IEXhe had pledged his shareholding in the issued share capital of the Company to be used against lending obligations as he may, from time to time become responsible for and which at 22 January 2009 amounted to £3mThe titles of three unencumbered Central London residential properties were also pledged as the security. 

The 9,069,000 Ordinary Shares held in the Company by Mr. Conlon currently represents 66% per cent. of the Company's entire issued share capital. 

No other Director of the Company has granted security over or entered into any financial instruments relating to any of their holdings of Ordinary Shares in the Company.

Contact:

First Derivatives plc

Brian Conlon

Tel: +44 (0)28 3025 2242

Charles Stanley Securities

Nominated Adviser

Russell Cook/Carl Holmes

Tel: +44 (0)20 7149 6000

Goodbody Stockbrokers 

IEX Adviser

Diane Hodgson/Linda Hickey

Tel: +353 1 667 0420

Stakeholder Communications 

Carl Whyte 

Lisa Nugent

Tel: +44 (0)28 9033 9949

Tel: +44 (0) 20 7903 5148

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSSEMFIDSUSEDF
Date   Source Headline
2nd Feb 20229:33 amRNSHolding(s) in Company
20th Jan 20227:00 amRNSDirectorate Change
17th Jan 20227:00 amRNSDirector/PDMR Shareholding
31st Dec 202110:10 amRNSTotal Voting Rights
13th Dec 20212:59 pmRNSIssue of Equity
9th Dec 20219:40 amRNSDirector/PDMR Shareholding
1st Dec 20211:55 pmRNSHolding(s) in Company
30th Nov 202110:52 amRNSTotal Voting Rights
18th Nov 20217:00 amRNSAppointment of Adviser
15th Nov 20215:12 pmRNSIssue of Equity
9th Nov 20218:48 amRNSHolding(s) in Company
2nd Nov 20217:00 amRNSResults for the six months ended 31 August 2021
11th Oct 20217:00 amRNSHolding(s) in Company
6th Oct 20214:27 pmRNSHolding(s) in Company
6th Oct 20217:00 amRNSNotice of Results
1st Sep 20219:29 amRNSTotal Voting Rights
25th Aug 20215:37 pmRNSIssue of Equity
11th Aug 20217:00 amRNSLTIP Award
30th Jul 20217:00 amRNSDirectorate Change
8th Jul 20215:23 pmRNSResult of AGM
2nd Jul 202111:47 amRNSHolding(s) in Company
30th Jun 202112:16 pmRNSTotal Voting Rights
22nd Jun 20215:44 pmRNSIssue of Equity
15th Jun 20211:20 pmRNSHolding(s) in Company
14th Jun 20215:05 pmRNSHolding(s) in Company
8th Jun 20215:19 pmRNSNotice of AGM & Change of Name
1st Jun 202110:31 amRNSTotal Voting Rights
26th May 20214:06 pmRNSHolding(s) in Company
25th May 20216:08 pmRNSIssue of Equity
18th May 20217:00 amRNSFull Year Results
13th Apr 20217:00 amRNSTrading Update
31st Mar 202110:29 amRNSTotal Voting Rights
3rd Mar 20216:13 pmRNSHolding(s) in Company
1st Mar 20217:00 amRNSAppointment of Eric Raab as KX CTO
1st Mar 20217:00 amRNSAppointment of Scott Matthews as CEO for MRP
26th Feb 20214:18 pmRNSIssue of Equity
26th Feb 20219:25 amRNSTotal Voting Rights
23rd Feb 20217:00 amRNSPartial sale of Quantile Technologies holding
15th Feb 20214:28 pmRNSIssue of Equity
29th Jan 20219:59 amRNSTotal Voting Rights
25th Jan 20216:18 pmRNSIssue of Equity
31st Dec 202011:17 amRNSTotal Voting Rights
9th Dec 20207:00 amRNSDirectorate Change
8th Dec 202012:46 pmRNSIssue of Equity
30th Nov 20209:35 amRNSTotal Voting Rights
16th Nov 20203:21 pmRNSHolding(s) in Company
13th Nov 20204:08 pmRNSHolding(s) in Company
12th Nov 20207:00 amRNSResult of secondary placing
30th Oct 20201:30 pmRNSIssue of Equity
27th Oct 20207:00 amRNSInterim results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.